Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3039% above fair value
$610.54−23.44 (-3.70%)
Close on Nov 20, 2026Market cap $17.08BP/E 33.9Yield –
Medpace net income
Net income is the profit left for shareholders after every expense, interest and tax.
Medpace's net income for the twelve months ending Sep 30, 2026 was $517.83M, up 19.6% year over year. For fiscal 2025 it was $451.12M, up 11.6% from the year before. The highest annual figure on record is $451.12M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $451.12M | +11.6% |
| FY2024 | Dec 31, 2024 | $404.39M | +43.0% |
| FY2023 | Dec 31, 2023 | $282.81M | +15.3% |
| FY2022 | Dec 31, 2022 | $245.37M | +34.9% |
| FY2021 | Dec 31, 2021 | $181.85M | +25.1% |
| FY2020 | Dec 31, 2020 | $145.38M | +44.7% |
| FY2019 | Dec 31, 2019 | $100.44M | +37.2% |
| FY2018 | Dec 31, 2018 | $73.19M | +87.1% |
| FY2017 | Dec 31, 2017 | $39.12M | +191.4% |
| FY2016 | Dec 31, 2016 | $13.43M | – |
| FY2015 | Dec 31, 2015 | -$8.67M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $137.46M | +23.7% |
| Q2 FY2026 | Jun 30, 2026 | $121.36M | +34.5% |
| Q1 FY2026 | Mar 31, 2026 | $123.87M | +8.1% |
| Q4 FY2025 | Dec 31, 2025 | $135.13M | +15.5% |
| Q3 FY2025 | Sep 30, 2025 | $111.14M | +15.3% |
| Q2 FY2025 | Jun 30, 2025 | $90.26M | +2.2% |
| Q1 FY2025 | Mar 31, 2025 | $114.60M | +11.7% |
| Q4 FY2024 | Dec 31, 2024 | $117.02M | +49.5% |
| Q3 FY2024 | Sep 30, 2024 | $96.43M | +36.7% |
| Q2 FY2024 | Jun 30, 2024 | $88.35M | +44.7% |
| Q1 FY2024 | Mar 31, 2024 | $102.59M | +40.7% |
| Q4 FY2023 | Dec 31, 2023 | $78.30M | +14.0% |
| Q3 FY2023 | Sep 30, 2023 | $70.55M | +6.9% |
| Q2 FY2023 | Jun 30, 2023 | $61.07M | +23.7% |
| Q1 FY2023 | Mar 31, 2023 | $72.89M | +18.9% |
| Q4 FY2022 | Dec 31, 2022 | $68.67M | +37.2% |
| Q3 FY2022 | Sep 30, 2022 | $66.03M | +35.9% |
| Q2 FY2022 | Jun 30, 2022 | $49.36M | +23.6% |
| Q1 FY2022 | Mar 31, 2022 | $61.31M | +41.6% |
| Q4 FY2021 | Dec 31, 2021 | $50.03M | -1.6% |
| Q3 FY2021 | Sep 30, 2021 | $48.57M | +17.2% |
| Q2 FY2021 | Jun 30, 2021 | $39.93M | +65.7% |
| Q1 FY2021 | Mar 31, 2021 | $43.31M | +49.6% |
| Q4 FY2020 | Dec 31, 2020 | $50.87M | +70.6% |
| Q3 FY2020 | Sep 30, 2020 | $41.46M | +72.9% |
| Q2 FY2020 | Jun 30, 2020 | $24.10M | -12.2% |
| Q1 FY2020 | Mar 31, 2020 | $28.95M | +50.8% |
| Q4 FY2019 | Dec 31, 2019 | $29.81M | +31.0% |
| Q3 FY2019 | Sep 30, 2019 | $23.98M | +24.2% |
| Q2 FY2019 | Jun 30, 2019 | $27.46M | +65.7% |
| Q1 FY2019 | Mar 31, 2019 | $19.20M | +31.9% |
| Q4 FY2018 | Dec 31, 2018 | $22.76M | +101.6% |
| Q3 FY2018 | Sep 30, 2018 | $19.31M | +96.4% |
| Q2 FY2018 | Jun 30, 2018 | $16.57M | +73.4% |
| Q1 FY2018 | Mar 31, 2018 | $14.55M | +72.3% |
| Q4 FY2017 | Dec 31, 2017 | $11.29M | – |
| Q3 FY2017 | Sep 30, 2017 | $9.83M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.55M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.45M | – |
| Q4 FY2016 | Dec 31, 2016 | -$21.00K | – |
See a number that looks wrong?